NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response.

  1. Abemaciclib has been integrated into the NCCN Guidelines for certain patients with high-risk early-stage disease. What data is needed for ribociclib to find a similar position in the guidelines?
  2. What are the guideline recommendations for monitoring for response to systemic treatment in breast cancer? What outcomes are most important when monitoring response to treatment?
Related Videos
timothy caulfield, JD
dr ibrahim aldoss
dr anna sureda
Related Content
CH LogoCenter for Biosimilars Logo